Baltimore-based company expands senior leadership team for continued growth

BALTIMORE, MD. (July 24, 2019)

emocha, a comprehensive medication adherence solution that empowers patients to take their medications, announced today new hires in support of its continued expansion. New leaders include Ramon Castro as Chief Technology Officer (CTO), Carl Kirts as Vice President of Growth & Market Development, and Aaron Sorenson as Senior Director of Data & Analytics. In addition, Michael Cohen was promoted to Chief Architect after joining emocha as a lead software engineer in 2017.

“We are ecstatic to add Ramon, Carl, and Aaron to our team, as well as recognize Michael in his well-deserved new role,” said Sebastian Seiguer, CEO at emocha. “emocha’s incredibly talented team has developed a solution to one of healthcare’s deadliest and costliest challenges: medication nonadherence.” 

emocha’s new CTO, Ramon, has worked in the technology industry since 1992, with 14 years of programming experience before moving to upper-level management roles. His diverse expertise includes backend and frontend development, infrastructure, testing, automation, data warehousing, analytics, security, and compliance for companies ranging from small startups to large enterprises. Most recently, Ramon served as Vice President of Technology for a2z Inc., a Columbia, Maryland-based technology company that was recently acquired by Personify Corp. He has served in leadership roles at multiple Maryland organizations throughout his career. 

As Vice President of Growth & Market Development, Carl is responsible for bringing emocha to markets, developing strategic partnerships, and leading marketing initiatives. He has deep knowledge of the challenges facing healthcare systems, with extensive sales, go-to-market strategy and strategic partnership experience across a variety of healthcare technology solutions. Carl comes to emocha from virtual care company Carena, which was acquired by American Well. He was an early member of Baltimore-based Visicu, which went public in 2006 before being purchased by Philips Healthcare in 2008. 

Aaron helps customers gain actionable insights into medication adherence trends as emocha’s Senior Director of Data & Analytics. He has worked in medical informatics and research-data analytics for 15 years in both the private sector — including roles at Digital Science, GE Healthcare, and IBM — and at academic medical centers — such as the Schools of Medicine at Temple University and Johns Hopkins University. Aaron leverages public-cloud offerings to accelerate data workflows and holds a number of cloud certifications, including Google Data Engineer and Amazon Machine Learning.  

For three years, Michael has continuously demonstrated value, dedication, and boundless curiosity as a lead software engineer at emocha. In his new role as Chief Architect, he is responsible for the development and delivery of emocha’s technology solution. Michael is a full stack developer at emocha with 15 years of experience in software development. Before joining emocha, Michael led software development at the Johns Hopkins Technology Innovation Center. 

Medication nonadherence remains a significant yet preventable challenge that leads to high costs across the country’s health system and worse outcomes for patients. The new additions to the team will bolster emocha’s growth in new markets as it continues its focus on supporting patient-centered care, and preventing avoidable emergency visits, hospitalizations, and readmissions.

About emocha Mobile Health

emocha empowers every patient to take every dose of medication through video technology and scalable human engagement. Patients use a smartphone application to video record themselves taking their medication, while care teams use a secure web portal to assess adherence and engage with patients. The platform is being used by public health departments, clinical trials, hospitals, health centers, and managed care organizations to radically improve medication adherence for patients with tuberculosis, opioid use disorder, hepatitis C, diabetes, and other chronic and infectious diseases. Learn more at

Contact: Janet Hughes |